Publications by authors named "Shonali Midha"

Claim this Profile
P
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, Andrew J Portuguese, Surbhi Sidana, Shonali Midha

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.
Matthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, Saurabh S Zanwar, Utkarsh Goel, Shonali Midha

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma.
Clifton C Mo, Yuxin Liu, Monique A Hartley-Brown, Omar Nadeem, Shonali Midha

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.
Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Binod Dhakal, Othman S Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Shonali Midha

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Clifton C Mo, Yuxin Liu, Omar Nadeem, Shonali Midha, Jacob P Laubach

Expert Opin Emerg Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.
Rahul Banerjee, Meera Mohan, Kai Rejeski, Benjamin R Puliafito, Diana D Cirstea, Shonali Midha

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.
Jessica S Little, Angelica Medina Pena, E Bridget Kim, Andrew J Yee, Omar Nadeem, Shonali Midha

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Shonali Midha

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, Shonali Midha

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Shonali Midha

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu, Shonali Midha

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Jack Khouri, Danai Dima, Hong Li, Doris Hansen, Surbhi Sidana, Shonali Midha

Transplant Cell Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, Adam S Sperling, Shonali Midha

Expert Rev Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Shonali Midha

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.
Rahul Banerjee, Yelak Biru, Craig E Cole, Beth Faiman, Shonali Midha

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Shonali Midha

Lancet Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Aimaz Afrough, Hamza Hashmi, Doris K Hansen, Surbhi Sidana, Chul Ahn, Shonali Midha

Blood Cancer J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Surbhi Sidana, Lauren C Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Shonali Midha

Haematologica· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma.
Monique A Hartley-Brown, Clifton C Mo, Omar Nadeem, Shonali Midha, Jacob P Laubach

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones.
Maho Terashita, Umut Selamet, Shonali Midha, Omar Nadeem, Jacob Laubach

Kidney Int Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy.
Clifton C Mo, Monique A Hartley-Brown, Shonali Midha, Paul G Richardson

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
Shonali Midha, Monique A Hartley-Brown, Clifton C Mo, Shahrier Hossain, Omar Nadeem

Expert Opin Drug Saf· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor: Targeting a novel pathway in multiple myeloma.
Clifton C Mo, Andrew J Yee, Shonali Midha, Monique A Hartley-Brown, Omar Nadeem

EJHaem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis